Literature DB >> 6487349

Nonenzymatic glucosylation of human serum albumin and its influence on binding capacity of sulfonylureas.

S Tsuchiya, T Sakurai, S Sekiguchi.   

Abstract

To estimate the functional change occurring in human serum albumin by nonenzymatic glucosylation, glucosylated human serum albumin was prepared by in vitro incubation with glucose. The rate of glucosylation proceeded as a first-order reaction. The binding of sulfonylureas to serum albumin was determined by equilibrium gel filtration. Through this method, it was possible to estimate the binding capacity of a low water solubility drug with a high affinity to protein. The amounts of the sulfonylureas bound to glucosylated HSA decreased by 44% with tolazamide and acetohexamide, 50% with glibenclamide, and 52% with tolbutamide, compared to human serum albumin (HSA). This suggests that a high concentration of glucosylated HSA in diabetic patients may possibly cause an increase in free drug concentration exceeding normal levels. This study shows that the decrease in the binding capacity of sulfonylureas with protein is due to the modification of albumin molecules by the covalent binding of glucose.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6487349     DOI: 10.1016/0006-2952(84)90595-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  16 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Characterization of the binding of sulfonylurea drugs to HSA by high-performance affinity chromatography.

Authors:  K S Joseph; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-06-01       Impact factor: 3.205

3.  Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats.

Authors:  P B Inskeep; A E Reed; R A Ronfeld
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

Review 4.  The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Authors:  R E Ferner; S Chaplin
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

5.  Chromatographic analysis of the effects of fatty acids and glycation on binding by probes for Sudlow sites I and II to human serum albumin.

Authors:  Jeanethe Anguizola; Erin Debolt; D Suresh; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-10-09       Impact factor: 3.205

Review 6.  Review: modifications of human serum albumin and their binding effect.

Authors:  Philbert Lee; Xiaoyang Wu
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

7.  Binding of tolbutamide to glycated human serum albumin.

Authors:  K S Joseph; Jeanethe Anguizola; David S Hage
Journal:  J Pharm Biomed Anal       Date:  2010-09-15       Impact factor: 3.935

8.  Drug-protein binding kinetics in patients with type I diabetes.

Authors:  W Wörner; A Preissner; N Rietbrock
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Protein binding of digitoxin, valproate and phenytoin in sera from diabetics.

Authors:  J Doucet; J Fresel; G Hue; N Moore
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 10.  Review: Glycation of human serum albumin.

Authors:  Jeanethe Anguizola; Ryan Matsuda; Omar S Barnaby; K S Hoy; Chunling Wa; Erin DeBolt; Michelle Koke; David S Hage
Journal:  Clin Chim Acta       Date:  2013-07-24       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.